Proprioception in Parkinson's disease is acutely depressed by dopaminergic medications

J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):607-10. doi: 10.1136/jnnp.71.5.607.

Abstract

Objectives: Impaired proprioception has been previously reported in patients with Parkinson's disease. It was hypothesised that dopaminergic medications transiently depress proprioception, with amplification of adventitious movements as a result. This study tested for effects on proprioception of dopaminergic drugs, and for associations between such effects and drug induced dyskinesias.

Methods: In 17 patients with Parkinson's disease, arm proprioception was tested in the practically defined "off" state, and retested 1 hour after taking levodopa or dopamine agonist. Testing consisted of side to side comparison of elbow angle, matching the contralateral elbow angle, and spatial recall of an unrestrained arm.

Results: Proprioception deteriorated as hypothesised, reaching significance by one tailed t test for each of the three tasks. The relative deterioration (and the 95% lower confidence bound for estimated deterioration) was 31% (4%) for side to side elbow comparison, was 27% (11%) for accuracy in matching the contralateral elbow angle, and was 11% (0%) for spatial recall. Dyskinetic (n=6) and non-dyskinetic (n=11) patients did not differ significantly in these effects on proprioception. Control subjects (n=6) and untreated parkinsonian subjects (n=5) did not significantly differ from the parkinsonian patients in the off state.

Conclusions: Administration of levodopa and dopamine agonists were associated with a modest acute suppression in central responsiveness to joint position. It is speculated that compensatory exaggerated movement could account in part for the phenomenon of drug induced dyskinesias.

MeSH terms

  • Acute Disease
  • Adult
  • Aged
  • Dopamine Agonists / administration & dosage
  • Dopamine Agonists / adverse effects*
  • Drug Administration Schedule
  • Female
  • Humans
  • Levodopa / administration & dosage
  • Levodopa / adverse effects*
  • Male
  • Middle Aged
  • Parkinson Disease / physiopathology*
  • Severity of Illness Index
  • Somatosensory Disorders / chemically induced*
  • Somatosensory Disorders / diagnosis

Substances

  • Dopamine Agonists
  • Levodopa